leisure time -WSS

leisure time

author：focus 2025-09-28 23:30:34 - browse：3974

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Readout Newsletter: Beam, Prozac, "TechBio" and more

WSS

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

CDC advisory group OKs chikungunya vaccine

Redefining sustainability for the pharmaceutical industry

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

Driven by the pandemic, applicants flood public health schools

explore

leisure time

explore

Walensky prepares to leave CDC — and Congress — behind

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Continuity nursing helped my family in our darkest PICU moments

Doctor of U.S. President Joe Biden says he is fit for duty

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Cholera vaccine supplies dangerously low, outbreaks surging

What does generative AI mean for health care? We asked experts

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

Walensky prepares to leave CDC — and Congress — behind

Change Healthcare cyberattack shows risk of industry consolidation

Wikipedia

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Study fuels hope CAR

Neuroscience renaissance leads to new crop of psychiatric drugs

Hospitals struggle to profit from CAR

Redefining sustainability for the pharmaceutical industry

explore

entertainment

entertainment

explore